Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A recent publication from the Powrie group at the Kennedy Institute of Rheumatology has described a novel mechanism by which the commensal pathogen Heliobacter hepaticus maintains its niche in the intestinal environment.

The work, led by Dr Camille Danne in Prof Fiona Powrie's group, describes the effects of a newly described H. hepaticus secreted polysaccharide on intestinal macrophages, promoting a pro-repair and anti-inflammatory gene signature and effector phenotype.

The discovery of this mechanism provides a better understanding of the potential means of molecular crosstalk between key host cells in the gut and commensal bacteria. By further understanding the pathways that promote tolerance and normal homeostasis, these same pathways can potentially be enhanced in order to restore balance after disruptive challenges and interventions such as antibiotic treatment, stress and food allergy, as well as to re-establish a balanced host–microbe dialogue in chronic inflammation.

The study, carried out in collaboration with Prof Simon Arthur's group in the University of Dundee, was published in Cell Host and Microbe earlier this month and can be accessed here, as was a commentary on the paper from the Kullberg lab which can be found here.

Similar stories

The Kennedy Institute launches its single cell facility

We spoke to Irina Udalova and Stephen Sansom about the Kennedy’s new single cell facility and how it will enhance research at the Institute and beyond.

New drug offers hope for people with hand osteoarthritis

A new study, published in Science Translational Medicine by researchers at the University of Oxford has identified that Talarozole, a drug that is known to increase retinoic acid, was able to prevent osteoarthritis (OA) in disease models.

Professor Michael Dustin appointed new Chair in Molecular Immunology

A generous gift from the Kennedy Trust for Rheumatology Research has enabled the creation of a new Chair in Molecular Immunology at the University of Oxford.

The Kennedy’s research strongly endorsed following independent review

We recently welcomed our Scientific Advisory Board (SAB) and the Kennedy Trust Scientific Review Board (TSRB) to the Institute to review our current activities and future plans.

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

Mathematician boosts data science research at the Kennedy Institute

Welcome to Yang Luo who has joined the Kennedy Institute as the Principal Investigator of the Luo Group. Her lab is leading the investigation into how genetic variations contribute to diseases of the immune system.